文献速递脑血管病

接受口服抗凝药治疗的心房颤动患者复发性缺血性卒中

Recurrent Ischemic Stroke in Patients With Atrial Fibrillation While Receiving Oral Anticoagulants.
PubMed 文献 · JAMA Neurol · 2024-01-01

丹麦全国性队列研究纳入2014年1月至2021年12月出院后开始或重启口服抗凝药(OAC)的50岁及以上心房颤动合并缺血性卒中患者8119例,随访至2022年6月。平均随访2.9年,663例发生复发性缺血性卒中,其中533例(80.4%)复发时仍在服用OAC。停用OAC者复发性缺血性卒中风险高于持续服药者(aOR 2.13,95%CI 1.57-2.89)。

要点

  • 心房颤动患者接受OAC二级预防后复发性缺血性卒中和死亡率仍较高。
  • 停用OAC与复发性缺血性卒中风险升高相关(aOR 2.13,95%CI 1.57-2.89)。
  • 作者强调应维持OAC治疗并改进心房颤动患者的二级卒中预防。

核心结论

  • 心房颤动患者接受OAC二级预防后复发性缺血性卒中和死亡风险仍较高,停用OAC使复发性缺血性卒中风险较持续服药者翻倍。

研究设计与样本

  • 丹麦全国性队列研究,纳入2014年1月至2021年12月出院后开始或重启OAC治疗的50岁及以上心房颤动合并缺血性卒中患者,随访至2022年6月。
  • 研究队列8119例,其中男性4392例(54.1%),平均(标准差)年龄78.4(9.6)岁,CHA2DS2-VASc评分中位数(四分位距)4.0(3.0-5.0)。
  • 在队列内进行巢式病例对照分析,将复发性缺血性卒中患者与尚未发生卒中的OAC治疗患者匹配。
  • 数据分析时间为2023年5月25日至2024年4月18日。

主要发现

  • 平均(标准差)随访2.9(2.2)年,663例发生复发性缺血性卒中,其中533例(80.4%)复发时正在服用OAC。
  • 1年复发性缺血性卒中粗累积发生率为4.3%(95%CI,5.9%-7.1%),全因死亡粗累积发生率为15.4%(95%CI,14.7%-16.2%)。
  • 停用OAC者复发性缺血性卒中89例(13.4%),对照180例(6.8%),校正比值比(aOR)为2.13(95%CI,1.57-2.89)。

临床怎么用

  • 原文结论指出应重视OAC的持续使用,并需要改进心房颤动患者的二级卒中预防。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with atrial fibrillation (AF) can have an ischemic stroke (IS) despite oral anticoagulant (OAC) treatment. Knowledge regarding the association between OAC discontinuation and the subsequent risk of recurrent IS in patients with AF is limited. OBJECTIVES: To determine the risk of recurrent IS in patients with AF receiving OAC and to evaluate the association between OAC discontinuation and the risk of recurrent IS. DESIGN, SETTING, AND PARTICIPANTS: This is a nationwide cohort study of patients aged 50 years or older in Denmark who had AF and an IS (entry IS) and were initiating or restarting subsequent OAC treatment after being discharged between January 2014 and December 2021. Patients were followed up for recurrent IS until June 2022. Within this study cohort, a nested case-control analysis was performed in which patients with recurrent IS were matched to patients receiving OAC who had not yet experienced a stroke. Data were analyzed from May 25, 2023, to April 18, 2024. EXPOSURE: Use of OAC at the time of recurrent IS or the equivalent date in matched controls based on redeemed prescriptions. MAIN OUTCOMES AND MEASURES: The primary outcome was recurrent IS. Crude and adjusted cumulative incidences of recurrent IS and all-cause mortality were calculated in cohort analyses, and adjusted odds ratios (aORs) were determined for recurrent IS associated with OAC discontinuation in nested case-control analyses. RESULTS: The study cohort included 8119 patients (4392 [54.1%] male; mean [SD] age, 78.4 [9.6] years; median (IQR) CHA2DS2-VASc score, 4.0 [3.0-5.0]). Over a mean (SD) follow-up of 2.9 (2.2) years, 663 patients had a recurrent IS, of whom 533 (80.4%) were receiving OAC at the time of their recurrent IS. The crude cumulative incidence of recurrent IS at 1 year was 4.3% (95% CI, 5.9%-7.1%), and the crude cumulative incidence of all-cause mortality was 15.4% (95% CI, 14.7%-16.2%). Adjusted analysis showed similar results. Patients who discontinued OACs had a higher risk of recurrent IS (89 cases [13.4%], 180 controls [6.8%]; aOR, 2.13; 95% CI, 1.57-2.89) compared with patients still receiving OAC. CONCLUSIONS AND RELEVANCE: The risks of recurrent IS and mortality were high in patients with AF despite secondary prevention with OAC, and OAC discontinuation doubled the risk of recurrent IS compared with patients who continued OAC. This finding highlights the importance of OAC continuation and the need for improved secondary stroke prevention in patients with AF.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Hindsholm MF, García Rodríguez LA, Brandes A, et al. Recurrent Ischemic Stroke in Patients With Atrial Fibrillation While Receiving Oral Anticoagulants. JAMA Neurol. 2024. PMID: 38913390. doi:10.1001/jamaneurol.2024.1892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。